Skip to main content
. 2012 Jan 18;32(3):841–849. doi: 10.1523/JNEUROSCI.4461-11.2012

Table 3.

SPM results showing the brain regions in which intravenous MP increased DA (decreased D2/D3 receptor availability) combined for treatment-naive and long-term treatments and SPM results showing the brain regions in which the DA increases induced by intravenous MP were larger for the naive than for the long-term treatment (Naive vs chronic)

BA/nucleus Cluster size x y z F value pFWE-CORR T value puncorr
Placebo versus MP
    Striatum 3721 0.000
        R putamen 30 −8 2 336
        L putamen −24 −6 2
        L ventral striatum −6 14 −6
    L inferior temporal 3910 0.000
        BA 20 −28 −14 −46 61
−58 −58 −32
−12 −4 −40
    L middle frontal 472 0.000
        BA 11 −24 48 −24 56
−26 40 −26
    R inferior frontal 2457 0.000
        BA 46 50 44 2 56
42 54 14
32 64 6
    R Uncus 263 0.001
        BA 36 30 −14 −44 46
14 −6 −36
    R middle frontal 331 0.006
        BA 11 30 34 −28 36
36 42 −24
32 26 −36
    Midbrain 271 12 −14 −16 32 0.02
4 −10 −16
Naive versus chronic
    Striatum 533
        L putamen −20 8 6 3.28 0.001
        L ventral putamen −24 −6 −4 2.93 0.002
    Striatum 505
        R ventral striatum 24 −10 −8 2.89 0.002
        R putamen 30 −4 2 2.79 0.003

For the naive versus long-term treatment comparison, all four coordinates have voxel-level p < 0.026, corrected for multiple comparisons (familywise error). There were no regions in which the effect of intravenous MP was greater for long-term treatment than for the treatment-naive condition. L, Left; R, right.